228 related articles for article (PubMed ID: 36038743)
1. Neuroendocrine neoplasms in the context of inherited tumor syndromes: a reappraisal focused on targeted therapies.
Ruggeri RM; Benevento E; De Cicco F; Fazzalari B; Guadagno E; Hasballa I; Tarsitano MG; Isidori AM; Colao A; Faggiano A;
J Endocrinol Invest; 2023 Feb; 46(2):213-234. PubMed ID: 36038743
[TBL] [Abstract][Full Text] [Related]
2. [Inherited tumor syndromes of gastroenteropancreatic and thoracic neuroendocrine neoplasms].
Couvelard A; Scoazec JY
Ann Pathol; 2020 Apr; 40(2):120-133. PubMed ID: 32035641
[TBL] [Abstract][Full Text] [Related]
3. Molecular genetics of gastroenteropancreatic neuroendocrine tumors.
Starker LF; Carling T
Curr Opin Oncol; 2009 Jan; 21(1):29-33. PubMed ID: 19125015
[TBL] [Abstract][Full Text] [Related]
4. The genetics of neuroendocrine tumors.
Öberg K
Semin Oncol; 2013 Feb; 40(1):37-44. PubMed ID: 23391111
[TBL] [Abstract][Full Text] [Related]
5. Indications for genetic study in gastro-entero-pancreatic and thoracic neuroendocrine tumors.
Araujo-Castro M
Endocrinol Diabetes Nutr (Engl Ed); 2023 Mar; 70 Suppl 1():63-73. PubMed ID: 36396595
[TBL] [Abstract][Full Text] [Related]
6. Distinct DNA Methylation Signatures in Neuroendocrine Tumors Specific for Primary Site and Inherited Predisposition.
Tirosh A; Killian JK; Petersen D; Zhu YJ; Walker RL; Blau JE; Nilubol N; Patel D; Agarwal SK; Weinstein LS; Meltzer P; Kebebew E
J Clin Endocrinol Metab; 2020 Oct; 105(10):3285-94. PubMed ID: 32706863
[TBL] [Abstract][Full Text] [Related]
7. [Associated gastroenteropancreatic neuroendocrine tumours to familiar syndromes].
Lecumberri Pascual E
Endocrinol Nutr; 2009 Apr; 56 Suppl 2():10-5. PubMed ID: 19627764
[TBL] [Abstract][Full Text] [Related]
8. Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies.
Ito T; Lee L; Jensen RT
Expert Opin Pharmacother; 2016 Nov; 17(16):2191-2205. PubMed ID: 27635672
[TBL] [Abstract][Full Text] [Related]
9. Management of gastroentero-pancreatic neuroendocrine tumors (GEP-NETs).
Desai KK; Khan MS; Toumpanakis C; Caplin ME
Minerva Gastroenterol Dietol; 2009 Dec; 55(4):425-43. PubMed ID: 19942827
[TBL] [Abstract][Full Text] [Related]
10. The efficacy of everolimus and sunitinib in patients with sporadic or germline mutated metastatic pancreatic neuroendocrine tumors.
Nuñez JE; Donadio M; Filho DR; Rego JF; Barros M; Formiga MN; Lopez R; Riechelmann R
J Gastrointest Oncol; 2019 Aug; 10(4):645-651. PubMed ID: 31392045
[TBL] [Abstract][Full Text] [Related]
11. Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline.
Del Rivero J; Perez K; Kennedy EB; Mittra ES; Vijayvergia N; Arshad J; Basu S; Chauhan A; Dasari AN; Bellizzi AM; Gangi A; Grady E; Howe JR; Ivanidze J; Lewis M; Mailman J; Raj N; Soares HP; Soulen MC; White SB; Chan JA; Kunz PL; Singh S; Halfdanarson TR; Strosberg JR; Bergsland EK
J Clin Oncol; 2023 Nov; 41(32):5049-5067. PubMed ID: 37774329
[TBL] [Abstract][Full Text] [Related]
12. Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies.
Jensen RT; Berna MJ; Bingham DB; Norton JA
Cancer; 2008 Oct; 113(7 Suppl):1807-43. PubMed ID: 18798544
[TBL] [Abstract][Full Text] [Related]
13. Molecular genetics of gastroenteropancreatic neuroendocrine tumors.
Toumpanakis CG; Caplin ME
Am J Gastroenterol; 2008 Mar; 103(3):729-32. PubMed ID: 18341492
[TBL] [Abstract][Full Text] [Related]
14. Somatic and germline mutations in NETs: Implications for their diagnosis and management.
Minnetti M; Grossman A
Best Pract Res Clin Endocrinol Metab; 2016 Jan; 30(1):115-27. PubMed ID: 26971848
[TBL] [Abstract][Full Text] [Related]
15. Advances in the systemic treatment of neuroendocrine tumors in the era of molecular therapy.
Leung R; Lang B; Wong H; Chiu J; Yat WK; Shek T; Cho WY; Yau LC; Yau T
Anticancer Agents Med Chem; 2013 Mar; 13(3):382-8. PubMed ID: 23092266
[TBL] [Abstract][Full Text] [Related]
16. Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas.
Fazio N; Cinieri S; Lorizzo K; Squadroni M; Orlando L; Spada F; Maiello E; Bodei L; Paganelli G; Delle Fave G; de Braud F
Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S87-94. PubMed ID: 21129617
[TBL] [Abstract][Full Text] [Related]
17. Multiple neuroendocrine tumors of the pancreas in von Hippel-Lindau disease patients: histopathological and molecular genetic analysis.
Lubensky IA; Pack S; Ault D; Vortmeyer AO; Libutti SK; Choyke PL; Walther MM; Linehan WM; Zhuang Z
Am J Pathol; 1998 Jul; 153(1):223-31. PubMed ID: 9665483
[TBL] [Abstract][Full Text] [Related]
18. An Advanced Well-differentiated Pancreatic Neuroendocrine Carcinoma (NET-G3) Associated with Von Hippel-Lindau Disease.
Miki M; Kawabe K; Igarashi H; Abe T; Ohishi Y; Hashimoto R; Karashima T; Yamasaki I; Inoue K; Ito T; Ogawa Y
Intern Med; 2018 Jul; 57(14):2007-2011. PubMed ID: 29491307
[TBL] [Abstract][Full Text] [Related]
19. GEP- NETS UPDATE: Genetics of neuroendocrine tumors.
Crona J; Skogseid B
Eur J Endocrinol; 2016 Jun; 174(6):R275-90. PubMed ID: 27165966
[TBL] [Abstract][Full Text] [Related]
20. Tyrosine Kinase Inhibitors and Immunotherapy Updates in Neuroendocrine Neoplasms.
Mosalem O; Sonbol MB; Halfdanarson TR; Starr JS
Best Pract Res Clin Endocrinol Metab; 2023 Sep; 37(5):101796. PubMed ID: 37414652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]